Research Analysts Set Expectations for ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Eton Pharmaceuticals in a report issued on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.08 per share for the quarter, down from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Several other equities research analysts also recently commented on ETON. B. Riley reissued a “buy” rating and set a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday.

Eton Pharmaceuticals Trading Down 3.8 %

ETON opened at $14.22 on Friday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The company has a market cap of $370.45 million, a P/E ratio of -64.64 and a beta of 1.37. The company has a fifty day moving average price of $15.58 and a two-hundred day moving average price of $11.54.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC increased its position in shares of Eton Pharmaceuticals by 12.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock worth $14,898,000 after acquiring an additional 119,750 shares in the last quarter. Westside Investment Management Inc. grew its position in Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after purchasing an additional 33,275 shares in the last quarter. Mink Brook Asset Management LLC purchased a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $6,071,000. Cannell Capital LLC purchased a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $5,079,000. Finally, Parkman Healthcare Partners LLC increased its stake in Eton Pharmaceuticals by 6.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock valued at $3,688,000 after buying an additional 16,664 shares during the last quarter. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.